Nemolizumab Versus Dupilumab in the Treatment of Prurigo Nodularis: Systematic Literature Review and Network Meta-analysis - PubMed
3 hours ago
- #nemolizumab
- #prurigo nodularis
- #dupilumab
- Nemolizumab and dupilumab are FDA/EMA-approved treatments for prurigo nodularis (PN).
- Network meta-analysis suggests nemolizumab may have greater efficacy than dupilumab in reducing pruritus, with significant differences at various time points.
- Safety profiles of nemolizumab and dupilumab are similar based on treatment-emergent adverse events.
- The study acknowledges uncertainty for some endpoints and highlights the need for direct comparative trials.